肿瘤药学2018，Vol.8Issue(1)：53-56,4.DOI:10.3969/j.issn.2095-1264.2018.01.12
甲磺酸阿帕替尼治疗二线化疗失败后晚期胃癌的效果观察
Clinical Observation of Aspirin Mesylate for Treatment of Patients with Advanced Gastric Cancer after Second-line Chemotherapy Failure
姚荣杰 1孟曼 1丁露 1毕金玲 1黄勇1
作者信息
- 1. 合肥市第二人民医院 肿瘤内科,安徽 合肥,230011
- 折叠
摘要
Abstract
Objective To investigate the clinical effect of apatinib mesylate for patients with advanced gastric cancer after second-line chemotherapy failure. Methods A retrospective analysis of 44 patients with advanced gastric cancer suffering more than second-line chemotherapy failure is made from March 2015 to July 2017 admitted to the hospital, they were divided into control group (n=22) and obser-vation group (n=22) according to the treatment scheme. The patients in control group were given the best symptomatic treatment, while the patients in observation group were treated with mesylate apatinib treatment. SF-36 scale evaluation for the quality of life, the quality of life, and clinical curative effect between the two groups before and after treatment was assessed. Results The treatment efficiency of patients in observation group after treatment in was 31.82%, while control group was 0%, the difference was statistically significant (P<0.05); the qual-ity of life scores had no significant difference between the two groups before treatment (P>0.05), physical function, psychological function, social function and material life score in the observation group after treatment is higher than those in the control group (P<0.05); the adverse reaction rate in two groups had significant difference (P<0.05). Conclusion Apatinib mesylate has ideal treatment effect for patients with advanced gastric cancer after failure of second-line chemotherapy, it is worthy of application and popularization.关键词
甲磺酸阿帕替尼/二线化疗/晚期胃癌/不良反应Key words
Mesylate apatinib/Second-line chemotherapy/Advanced gastric cancer/Adverse reaction分类
医药卫生引用本文复制引用
姚荣杰,孟曼,丁露,毕金玲,黄勇..甲磺酸阿帕替尼治疗二线化疗失败后晚期胃癌的效果观察[J].肿瘤药学,2018,8(1):53-56,4.
